Back to top
more

McKesson (MCK)

(Real Time Quote from BATS)

$586.81 USD

586.81
182,938

+1.07 (0.18%)

Updated Jul 24, 2024 12:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

3 Reasons to Retain DaVita (DVA) Stock to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

Reasons to Add Patterson Companies (PDCO) to Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

Sumit Singh headshot

Add These 4 Stocks With Impressive Interest Coverage Ratio

by Sumit Singh

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. MOH, DAL, ATO and MCK are strong enough to meet financial obligations.

Merit Medical (MMSI) Completes Enrollment in WRAPSODY Study

by Zacks Equity Research

Merit Medical (MMSI) is evaluating its device for treating stenosis/occlusion, WRAPSODY, in a pivotal study on patients undergoing hemodialysis. Primary data from the study is expected after six months.

McKesson (MCK) Q1 Earnings Beat Estimates, U.S. Sales Strong

by Zacks Equity Research

McKesson's (MCK) fiscal first-quarter 2024 results benefit from growth in the United States. Divestment hurts the International segment.

McKesson (MCK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

McKesson (MCK) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

McKesson (MCK) delivered earnings and revenue surprises of 24.27% and 6.55%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

DaVita (DVA) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) second quarter's top line.

Indrajit Bandyopadhyay headshot

Medical Device Aug 2 Earnings Roster: MCK, FMS & GKOS

by Indrajit Bandyopadhyay

Medical Device players are expected to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MCK, FMS and GKOS are likely to have performed this time.

Globus Medical (GMED) Gains on Innovation, Strategic Deal

by Zacks Equity Research

Globus Medical's (GMED) Enabling technology sales improvement is driven by strong performance of its robotic and imaging system.

Here's Why You Should Retain Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Bruker (BRKR) based on the strong performances of the Bruker BioSpin Group.

McKesson (MCK) to Report Q1 Earnings: Is a Beat in Store?

by Zacks Equity Research

McKesson's (MCK) fiscal first-quarter 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q3 sales.

CVS Health (CVS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

We expect brand price inflation, new product launch, higher utilization and new PBM clients to have contributed to second-quarter growth for CVS Health (CVS).

Sumit Singh headshot

Pick These 4 Stocks With Superb Interest Coverage Ratio

by Sumit Singh

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Lincoln Electric (LECO), McKesson (MCK), Atmos Energy (ATO) and O'Reilly (ORLY) are sound enough to meet financial obligations.

Henry Schein (HSIC) Set to Post Q2 Earnings: What Awaits?

by Zacks Equity Research

Henry Schein's (HSIC) second-quarter 2023 results are likely to be aided by the Dental business and new buyouts.

Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) second-quarter results are likely to reflect continued segmental strength.

Lantheus (LNTH) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Lantheus' (LNTH) second-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.

McKesson (MCK) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Is a Beat Likely for AmerisourceBergen (ABC) in Q3 Earnings?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal third-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) second-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.

Bio-Rad Laboratories (BIO) to Post Q2 Earnings: What Awaits?

by Zacks Equity Research

Bio-Rad Laboratories' (BIO) second-quarter 2023 results are likely to reflect an impressive performance across its Clinical Diagnostics business.

DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) second-quarter 2023 results are likely to reflect rising volumes across all channels.

What's in Store for West Pharmaceutical (WST) in Q2 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.